Sona Nanotech Receives ‘Deprioritization’ from FDA; Health Canada Evaluation Continues

You may also like

First Patient Dosed in Early Feasibility Study Trial of Its Cancer Therapy

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

Sona Successfully Completes FDA-required Toxicity Study